Biotech Values

[oc631]

Does anyone care to toss out any wild numbers as I honestly haven't seen any and I'm just curious about where VRUS could go in a best-case scenario?

Two years ago it was estimated that there was 300 million HCV cases worldwide. In the U.S. there are 3.4 million and in Europe there are 2.3 million. I can't tell you how many patients will undergo treatment with the P.I.'s in the U.S. (which of course is the premium market at $50,000 per patient) but this leaves 294 million people worldwide in need of better treatment. I'm a long-term investor in this company and I find it amusing that some intelligent people think the patient pool will be drained by the time PSI-7977 comes to market.


Here's a copy from a previous post I made on Yahoo. At the risk of repeating myself



The paradox to this story is you have a small/mid cap company in complete control of all the assets and IP that is needed by large pharma to rule the future of oral HCV treatment in all genotypes. Who will make the first bid? Who wants to dominate the HCV arena the way GILD dominated HIV? Just sit back, relax and don't worry about hedging your position.


What's your estimated fair value for this company?